CHAMPIONS ONCOLOGY INC (CSBR) Stock Price & Overview

NASDAQ:CSBR • US15870P3073

Current stock price

6.2 USD
-0.05 (-0.8%)
Last:

The current stock price of CSBR is 6.2 USD. Today CSBR is down by -0.8%. In the past month the price increased by 5.98%. In the past year, price decreased by -35.28%.

CSBR Key Statistics

52-Week Range5.5 - 9.9743
Current CSBR stock price positioned within its 52-week range.
1-Month Range5.5 - 6.34
Current CSBR stock price positioned within its 1-month range.
Market Cap
86.118M
P/E
N/A
Fwd P/E
60.78
EPS (TTM)
-0.05
Dividend Yield
N/A

CSBR Stock Performance

Today
-0.8%
1 Week
+5.08%
1 Month
+5.98%
3 Months
-14.13%
Longer-term
6 Months -5.56%
1 Year -35.28%
2 Years +26.53%
3 Years +54.23%
5 Years -45.13%
10 Years +70.33%

CSBR Stock Chart

CHAMPIONS ONCOLOGY INC / CSBR Daily stock chart

CSBR Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to CSBR. When comparing the yearly performance of all stocks, CSBR is a bad performer in the overall market: 86.57% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CSBR Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to CSBR. While CSBR is still in line with the averages on profitability rating, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CSBR Earnings

On March 12, 2026 CSBR reported an EPS of -0.02 and a revenue of 16.56M. The company missed EPS expectations (-121.79% surprise) and missed revenue expectations (-2.27% surprise).

Next Earnings DateJul 21, 2026
Last Earnings DateMar 12, 2026
PeriodQ3 / 2026
EPS Reported-$0.02
Revenue Reported16.56M
EPS Surprise -121.79%
Revenue Surprise -2.27%

CSBR Forecast & Estimates

7 analysts have analysed CSBR and the average price target is 12.24 USD. This implies a price increase of 97.42% is expected in the next year compared to the current price of 6.2.

For the next year, analysts expect an EPS growth of -72.8% and a revenue growth 3.41% for CSBR


Analysts
Analysts82.86
Price Target12.24 (97.42%)
EPS Next Y-72.8%
Revenue Next Year3.41%

CSBR Groups

Sector & Classification

CSBR Financial Highlights

Over the last trailing twelve months CSBR reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS decreased by -109.43% compared to the year before.


Income Statements
Revenue(TTM)56.94M
Net Income(TTM)2.49M
Industry RankSector Rank
PM (TTM) 4.27%
ROA 8.26%
ROE 59.76%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%-105.56%
Sales Q2Q%-2.81%
EPS 1Y (TTM)-109.43%
Revenue 1Y (TTM)13.54%

CSBR Ownership

Ownership
Inst Owners47.9%
Shares13.89M
Float10.18M
Ins Owners26.55%
Short Float %0.68%
Short Ratio11.06

CSBR Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
TMO THERMO FISHER SCIENTIFIC INC19.06174.596B
DHR DANAHER CORP22.99135.34B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28125.6140.288B
A AGILENT TECHNOLOGIES INC16.8531.614B
WAT WATERS CORP20.4428.451B
IQV IQVIA HOLDINGS INC13.1427.68B
MTD METTLER-TOLEDO INTERNATIONAL25.7324.37B
ILMN ILLUMINA INC23.118.238B
WST WEST PHARMACEUTICAL SERVICES29.5517.307B
MEDP MEDPACE HOLDINGS INC26.1112.874B
RVTY REVVITY INC15.859.668B
TEM TEMPUS AI INC-CL A N/A9.096B
TECH BIO-TECHNE CORP22.957.636B

About CSBR

Company Profile

CSBR logo image Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.

Company Info

IPO: 1988-11-30

CHAMPIONS ONCOLOGY INC

One University Plaza,, Suite 307

Hackensack NEW JERSEY 07601 US

CEO: Ronnie Morris

Employees: 213

CSBR Company Website

CSBR Investor Relations

Phone: 12018088400

CHAMPIONS ONCOLOGY INC / CSBR FAQ

What does CSBR do?

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.


Can you provide the latest stock price for CHAMPIONS ONCOLOGY INC?

The current stock price of CSBR is 6.2 USD. The price decreased by -0.8% in the last trading session.


What is the dividend status of CHAMPIONS ONCOLOGY INC?

CSBR does not pay a dividend.


What is the ChartMill rating of CHAMPIONS ONCOLOGY INC stock?

CSBR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What is the analyst forecast for CSBR stock?

7 analysts have analysed CSBR and the average price target is 12.24 USD. This implies a price increase of 97.42% is expected in the next year compared to the current price of 6.2.


Would investing in CHAMPIONS ONCOLOGY INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CSBR.


Can you provide the number of employees for CHAMPIONS ONCOLOGY INC?

CHAMPIONS ONCOLOGY INC (CSBR) currently has 213 employees.